The safeguards — and potential pitfalls — of having a power of attorney
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Some Acadia University staff working 4 days a week after successful pilot program
Some Acadia University staff are working four days a week instead of five this summer after a pilot program showed positive results. The university says about 90 per cent of full-time administrative employees participated in the pilot program last summer. They received the same pay for their work and did not have to work longer hours to make up for the day off. A group of researchers then surveyed staff satisfaction. The group found that the participants reported higher job satisfaction and a surge in leisure activities, from community involvement to new hobbies. "Ninety-seven per cent said it had a positive impact on their mental health and also their emotional well-being, and it also impacted their quality of life," said Rebecca Casey, a sociology professor at Acadia University and one of the researchers. This four-day work week is only back for the summer when there are fewer students, said the university in a statement, because it will be "all hands on deck" during the fall and winter semesters. The university said it allowed teams to choose their days off since each office has different workloads, deadlines and needs. In addition to faculty, senior leadership was excluded from the model, meaning the president and vice-presidents continued to work five days a week. Casey said a handful of people did have issues implementing the four-day work week, although the overwhelming majority found it positive. The researchers say the implementation of a shorter work week can also lead to higher recruitment and retention, as more people would like to work fewer days for the same pay and use that extra time for leisure. "Organizations are increasingly tasked with designing work structures prioritizing employee well-being while sustaining their daily operations and mandate," the report states. Casey says the results of the pilot program will be shown at a presentation in the United Kingdom this summer to further discuss what shorter work weeks could look like in the field. MORE TOP STORIES
Forbes
42 minutes ago
- Forbes
Why Did MP Materials Stock Jump 50% In A Single Day?
CANADA - 2025/06/13: In this photo illustration, the MP Materials logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) MP Materials Corp (NYSE:MP) has just experienced a significant breakthrough on Wall Street, and it can be attributed to one word: defense. In a decisive action to bolster the U.S. supply chain for rare earth magnets—essential elements for fighter jets, missiles, and electric vehicles—the Pentagon revealed a $400 million investment in MP Materials. This single move caused MP's stock price to surge by over 50% in a single day, reaching a multi-year maximum. Although MP stock has faced fluctuations, if you are looking for growth with less volatility than single stocks, the Trefis High Quality portfolio provides an alternative – having outperformed the S&P 500 and delivered returns exceeding 91% since its inception. The Department of Defense is currently the largest shareholder of the company, owning approximately 15% of MP's stock through a combination of preferred shares and warrants. This is a robust show of confidence, but it also indicates a clear message: the U.S. is seriously committed to achieving rare earth independence. For MP, this represents more than just financial gain. It's a strategic advantage. The agreement includes a 10-year price floor guarantee and a long-term supply contract—essentially ensuring revenue in a fluctuating market largely controlled by China. The financing will assist MP in completing its new '10X' magnet facility in Texas and increasing production at its Mountain Pass mine in California. Markets reacted swiftly. Investors view this as a pivotal turning point for the company, transforming it from a specialized miner into an essential part of national security. Year-to-date, the stock has risen over 180%, and analysts are quickly adjusting their forecasts. In summary? MP has evolved into more than just a mining enterprise. It has become a significant factor in the U.S. industrial and defense strategy—and the market is taking note. Not pleased by the unpredictable nature of MP stock? The Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has demonstrated a history of consistently outperforming the S&P 500 over the last four years. What accounts for this? Collectively, HQ Portfolio stocks have generated superior returns with reduced risk compared to the benchmark index; it's been less of a roller-coaster experience, as shown in HQ Portfolio performance metrics.
Yahoo
an hour ago
- Yahoo
Something Comically Bad Just Happened to the Inventor of Ozempic
Novo Nordisk, the Danish company behind Ozempic and Wegovy, made one very dumb decision a few years ago that's now poised to massively eat into its profits — a wild twist in the pharma company's saga, and an all-time cautionary tale for its peers. When watching an interview with the head of generic drugmaker Sandoz, Science magazine columnist Derek Lowe learned something incredible: that Novo failed to renew its Canadian patent on semaglutide, the active ingredient in the uber-expensive drugs Ozempic and Wegovy. Speaking to the biopharma industry outlet Endpoints News earlier this month, Sandoz CEO Richard Saynor dropped the information as an aside in a larger conversation about the company's plans to sell generic semaglutide in Canada in 2026 — the same year that Novo's patent expires there due to the filing oversight. "Canada, we filed and are waiting for approval once the data exclusivity expires sometime in Q1 next year," Saynor told Endpoints. "Interesting market. Novo never filed a patent in Canada." Saynor, to be clear, was not quite correct in saying Novo never filed for a semaglutide patent in Canada — but the truth of the matter is actually way funnier. Lowe learned, via trawling through Canadian patent records, that Novo last filed to renew its semaglutide patent in the great white north back in the year 2018. When the regulatory body that governs patents reminded the Danish manufacturer that it was time to pay the annual maintenance fee, a paltry $250, Novo hemmed and hawed about whether it wanted to pay for so long that it quite literally lapsed. Incredibly the Canadian patent office even gave the company a year-long grace period to make up for it, but the company never took the authorities up on the offer. "Once a patent has lapsed," the Canadian patent officials reminded Novo Nordisk in a letter viewed by Lowe, "it cannot be revived." As the Sandoz CEO remarked in his Endpoints interview, there's little doubt that "someone's lost their job" over the patent problem in Canada. Indeed, Saynor described that country as Novo's second-largest semaglutide market, and Ozempic sales in Canada garnered the pharma giant $2.5 billion CAD last year. "You gotta ask why. I don't think Canadians are disproportionately large," Saynor said. "There's clearly a dynamic, like insulin, with cross-border business. It's going to be interesting to see how that evolves." Novo has, notably, kept up with its patent fees in the US, and generic semaglutide won't hit American shelves until at least 2032 — but as Saynor alluded to, they might be able to drive up to Canada to get it next year. More on Ozempic: McDonald's in Trouble as Ozempic Takes Hold Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
